Modality
Radioligand
MOA
SOS1i
Target
GLP-1R
Pathway
Apoptosis
FTDSLEHS
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
Aug 2021
→ Oct 2029
Phase 1Current
NCT04921294
2,310 pts·HS
2021-08→2025-10·Recruiting
NCT06338651
1,598 pts·FTD
2024-08→2029-10·Terminated
3,908 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-265mo agoInterim· HS
2029-10-043.5y awayInterim· FTD
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Recruit…
P1
Termina…
Catalysts
Interim
2025-10-26 · 5mo ago
HS
Interim
2029-10-04 · 3.5y away
FTD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04921294 | Phase 1 | HS | Recruiting | 2310 | PASI75 |
| NCT06338651 | Phase 1 | FTD | Terminated | 1598 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C |